Urodynamix Reports Positive Results from Second Female UI Study

VANCOUVER, British Columbia, March 8, 2007 - Urodynamix Technologies Ltd. (TSX-V:URO) today reported positive results from a clinical study (“Female UI Study 2”). These results demonstrated that the Company’s URO-NIRS technology can be used to aid in the diagnosis of urinary incontinence (“UI”) in women.

“These study results suggest that NIRS can be used to identify activity in the bladder wall, and may be helpful in the assessment of women with common UI diseases,” stated principal investigator Dr. Sidney Radomski, MD, FRCSC, Associate Professor of Surgery (Urology) at the University of Toronto.

Based upon the results of the study, which were reviewed by the Company’s Medical Advisory Board, Urodynamix believes that its non-invasive NIRS procedure can provide clinically relevant information to physicians during the evaluation of patients with urinary incontinence and aid in the diagnosis and treatment.

“We are very pleased with the progress being made in bringing URO-NIRS technology closer to clinical application,” said Dr. Lynn Stothers, MD, FRCSC, Associate Professor of Urology/Surgery and Director of Research at the UBC Bladder Care Centre. “This technology may help doctors non-invasively assess and treat patients with UI, and could become a new standard of care.”

Female UI Study 2 Results

Female UI Study 2 was carried out from October 2006 to January 2007 and enrolled a total of 28 female subjects. Dr. Radomski studied 19 pathological female subjects, all of whom presented with symptoms of UI including stress urinary incontinence (“SUI”), overactive bladder (“OAB”) or related symptoms. During the same period, 9 healthy normal female subjects were studied at the UBC Bladder Care Centre by Dr. Stothers and Dr. Andrew Macnab, MD, FRCPC, FRCPCH, Professor of Pediatrics at UBC.

The study identified NIRS changes that correspond to physiological activity of the bladder, allowing the Company to develop a technique to help diagnose the presence or absence of UI in female subjects when NIRS is used in conjunction with non-invasive uroflow and/or catheter-based filling procedures.

The data showed that NIRS measurements of oxygenated hemoglobin (HbO2), deoxygenated hemoglobin (Hb), and cytochrome (Cyt) in subjects diagnosed with urinary incontinence differed measurably and significantly from normal subjects during the study. The study concluded that NIRS provided quantifiable evidence of pathologies in this study population, and further study will focus on categorizing different female pathologies.

This study confirmed that NIRS detected physiological activities in the bladder. Statistical analysis showed that significant changes in HbO2, Hb, and Cyt were detected in pathological versus normal subjects. The area under the ROC curve (a plot of the true positive rate against the false positive rate for a diagnostic test) for changes in the absolute concentrations of HbO2, Hb, and Cyt were 0.77, 0.76 and 0.78 respectively.

The data from Female UI Study 2 corroborate results obtained in a previous study carried out at the UBC Bladder Care Centre (see news release dated July 31, 2006 for details).

A study is being carried out by Drs. Lynn Stothers and Andrew Macnab at UBC Bladder Care Centre to examine the changes in Hb and HbO2 patterns that are associated with the common types of voiding dysfunction in women. The study results are anticipated to be released in the second quarter of this year.

About Urinary Incontinence (UI)

Stress urinary incontinence (SUI), the most prevalent form of incontinence among women, affects an estimated 30 million women in North America. SUI is defined as uncontrollable and involuntary loss of urine when abdominal pressure is placed on a weakened urethral sphincter muscle. It is caused by weakened pelvic floor muscles or damage to nerves that control the urinary sphincter due to pregnancy, childbirth, hysterectomy, menopause, obesity, or pelvic organ prolapse. The National Association for Continence estimates that women afflicted with SUI spend an average of $58,000 on treatment and management over their lifetime.

Overactive bladder (OAB) affects 17 million men and women in the United States, including 10 million men aged 40 and over. OAB occurs when the detrusor muscle of the bladder contracts without warning. Symptoms include frequent urination, urgency of urination, urge incontinence (involuntary loss of urine), and nocturia (night-time urination). The current standard of care involves the use of antimuscarinic drugs such as Detrol® (tolterodine) to help alleviate OAB symptoms. These drugs help regulate bladder contractions through their effects on the smooth muscle of the bladder (the detrusor muscle). In 2000, the estimated cost related to overactive bladder in the United States was nearly $14 billion. Treatment options include medication, pelvic muscle rehabilitation, behavioral therapy, neuromodulation and surgery.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company’s disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Craig Pamplin, PhD

Director, Corporate Development and Communications

Urodynamix Technologies Ltd.

Tel: (604) 638-0247

Email: cpamplin@urodynamix.com